NEWS
You can follow the latest news of MicroViable in this section
Alejandro Lucia, researcher at the European University and collaborator of Microviable Therapeutics, National Award for Research in Sports Medicine.
It is always a pleasure to work with prestigious researchers. Congratulations Alejandro Lucia! for the award received. A group of ten researchers from various institutions, including Alejandro Lucia, a researcher at the European University and [...]
Microviable announces 1.5 million € investment to advance the company´s microbiota-derived biotherapeutic products.
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]
Microviable will be attending Pharmabiotics Event 2022
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to [...]
Microviable Therapeutics is hiring!
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit [...]
Microviable Therapeutics to enter into a contractual agreement with BCD Bioscience.
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research [...]
Our co-founders and SAB scientific publications among the Top 100 in Cell and Molecular Biology
Last week, the Nature Group Scientific Reports journal published the top 100 most downloaded cell and molecular biology papers. This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human [...]